Your browser doesn't support javascript.
loading
First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis.
Alikhanova, N; Akhundova, I; Seyfaddinova, M; Mammadbayov, E; Mirtskulava, V; Rüsch-Gerdes, S; Bayramov, R; Suleymanova, J; Kremer, K; Dadu, A; Acosta, C D; Harries, A D; Dara, M.
Affiliation
  • Alikhanova N; Scientific Research Institute of Lung Disease, Baku, Azerbaijan.
  • Akhundova I; Scientific Research Institute of Lung Disease, Baku, Azerbaijan.
  • Seyfaddinova M; Scientific Research Institute of Lung Disease, Baku, Azerbaijan.
  • Mammadbayov E; Scientific Research Institute of Lung Disease, Baku, Azerbaijan.
  • Mirtskulava V; TADR Test & Evaluation Lead Biological Threat Reduction Program Branch of Battelle Memorial Institute, Atlanta, Georgia, USA.
  • Rüsch-Gerdes S; Forsungszentrum Borstel, Borstel, Germany.
  • Bayramov R; Lung Disease Department, Azerbaijan State Medical University, Baku, Azerbaijan.
  • Suleymanova J; World Health Organization (WHO) Country Office, Baku, Azerbaijan.
  • Kremer K; WHO Regional Office for Europe, Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, Copenhagen, Denmark.
  • Dadu A; WHO Regional Office for Europe, Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, Copenhagen, Denmark.
  • Acosta CD; WHO Regional Office for Europe, Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, Copenhagen, Denmark.
  • Harries AD; International Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.
  • Dara M; WHO Regional Office for Europe, Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, Copenhagen, Denmark.
Public Health Action ; 4(Suppl 2): S17-23, 2014 Oct 21.
Article in En | MEDLINE | ID: mdl-26393092
ABSTRACT

SETTING:

Civilian population of the Republic of Azerbaijan.

OBJECTIVES:

To determine patterns of anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis (TB) cases, and explore their association with socio-demographic and clinical characteristics.

DESIGN:

National cross-sectional survey conducted in 2012-2013.

RESULTS:

Of 789 patients (549 new and 240 previously treated) who met the enrolment criteria, 231 (42%) new and 146 (61%) previously treated patients were resistant to any anti-tuberculosis drug; 72 (13%) new and 66 (28%) previously treated patients had multidrug-resistant TB (MDR-TB). Among MDR-TB cases, 38% of new and 46% of previously treated cases had pre-extensively drug-resistant TB (pre-XDR-TB) or XDR-TB. In previously treated cases, 51% of those who had failed treatment had MDR-TB, which was 15 times higher than in relapse cases (OR 15.2, 95%CI 6-39). The only characteristic significantly associated with MDR-TB was a history of previous treatment (OR 3.1, 95%CI 2.1-4.7); for this group, history of incarceration was an additional risk factor for MDR-TB (OR 2.8, 95%CI 1.1-7.4).

CONCLUSION:

Azerbaijan remains a high MDR-TB burden country. There is a need to implement countrywide control and innovative measures to accelerate early diagnosis of drug resistance in individual patients, improve treatment adherence and strengthen routine surveillance of drug resistance.
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 / 3_ND Database: MEDLINE Type of study: Etiology_studies / Risk_factors_studies / Screening_studies Language: En Journal: Public Health Action Year: 2014 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 / 3_ND Database: MEDLINE Type of study: Etiology_studies / Risk_factors_studies / Screening_studies Language: En Journal: Public Health Action Year: 2014 Document type: Article